Pyoderma Gangrenosum – Drugs In Development, 2024
Powered by ![]()
Unlock hidden opportunities in the Pharmaceuticals industry
Empower your strategies with our Pyoderma Gangrenosum – Drugs In Development, 2024 report and make more profitable business decisions.
Pyoderma gangrenosum (PG) is one of a group of autoinflammatory disorder neutrophilic dermatoses. PG generally starts with a small bump resembling a spider bite that can rapidly enlarge, forming a very painful ulcer. It is usually associated with autoimmune diseases like ulcerative colitis, Crohn’s disease, and arthritis. It is diagnosed by its characteristic appearance and severe pain. Biopsy can be helpful in ruling out other causes of ulceration. Small ulcers are treated with topical steroid ointment, special dressings, oral anti-inflammatories, and antibiotics. Large ulcers can be treated with oral prednisolone, ciclosporin, baricitinib, and biological agents like infliximab, adalimumab, and etanercept.
The Pyoderma Gangrenosum drugs in development market research report provide comprehensive information on the therapeutics under development for Pyoderma Gangrenosum, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA), and molecule type. The report also covers the descriptive pharmacological action and product description of the therapeutics, and the latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Pyoderma Gangrenosum and features dormant and discontinued products.
Note:
* This is an “on-demand” report and will be delivered within 2 business days (excluding weekends and holidays) of the purchase.
* Certain sections in the report may be removed or altered based on the availability and relevance of data.
| Quick View – Pyoderma Gangrenosum | Key Targets |
|
|
| Key Mechanisms of Action |
|
||
| Key Routes of Administration |
|
||
| Key Molecule Types |
|
||
| Major Companies |
|
||
Scope
- Therapeutics in Development: Covering 5 molecules, with 5 developed by companies and the rest by universities/institutes.
- Analysis Parameters: Offering insights by stage of development, drug target, MoA, RoA, and molecule type for a comprehensive overview.
- Pharmacological Insights: Understand the descriptive pharmacological action of therapeutics.
- Development History: Access the complete research and development history.
- Latest News and Press Releases: Stay updated with the latest developments through comprehensive news coverage.
Reasons to Buy
- Holistic insights: Understand the broad spectrum of Pyoderma Gangrenosum therapeutics, aiding strategic decision-making with insights into stages, targets, MoA, RoA and molecule types.
- Pipeline Exploration: Explore the detailed Pyoderma Gangrenosum pipeline, offering nuanced analysis of drug targets, mechanisms of action and routes of administration for varied decision-making.
- Comprehensive R&D: Access thorough R&D histories, providing a comprehensive understanding of Pyoderma Gangrenosum treatments for adaptable decision-making.
- Save valuable hours: Identify key players steering innovation in therapeutics, enabling strategic partnerships.
Key Players
BioMarck Pharmaceuticals LtdBristol-Myers Squibb Co
InflaRx NV
Novartis AG
Swiss Biopharma Med GmbH
Table of Contents
Table
Figures
Frequently asked questions
Related reports
View more Pyoderma Gangrenosum reports